Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining carboxytherapy with standard treatment for androgenetic alopecia in men significantly improved clinical outcomes and patient satisfaction compared to standard treatment alone over a 24-week period.

In an outpatient cardiology center, this study found that introducing the AHA/ACC ABI screening protocol significantly increased the frequency of ABI ordering by 31.6% for symptomatic patients.

This analysis of the innovation process in Azerbaijan's oil and gas industry suggests that information technology plays a crucial role in achieving sustainable development by integrating new scientific knowledge with technology.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

This review highlights recent progress in developing androgen receptor degraders, such as PROTACs, for treating castration-resistant prostate cancer, and notes that several have entered phase I or II clinical trials, showcasing potential to address drug resistance challenges.

In this study, candidate compound 39 demonstrated potent androgen receptor antagonism and faster hair-growth efficacy in a mouse model compared to pyrilutamide, while maintaining favorable safety and pharmacokinetic profiles, suggesting potential for topical use in androgenic alopecia.

This study suggests that while Nanostring profiling identifies important processes in resolving MA-ARDS, solely targeting late-stage resolution by altering SPM production is not enough. The researchers conclude that combining multi-targeted adjunctive therapies with antimalarial drugs may be necessary to enhance survival and recovery.

Tapinarof cream at 1% concentration is effective and better tolerated for treating atopic dermatitis than the 2% concentration.

In this study, amitraz was found to be an effective and well-tolerated treatment for resolving sarcoptic mange in alpacas, demonstrating no relapse over a 10-month follow-up.

This letter discusses the potential of the Janus kinase 1 inhibitor abrocitinib for treating oral lichen planus but provides no new research findings.

This source reports that the approval of baricitinib and ritlecitinib, which are JAK inhibitors, has marked a significant advancement in treating severe alopecia areata (AA), and suggests that additional treatments with new mechanisms may further improve patient outcomes in the future.

This study found that alopecia areata significantly impacts patients' quality of life irrespective of hair loss severity, and concluded that the newer assessment tools AAPPO and AASIS better capture this impact compared to the traditional SALT measure.

This study found that VE-cadherin and Alk1, traditionally linked to vascular functions, also play crucial roles in maintaining nerve homeostasis in mice during hair growth cycles by modulating certain cell populations.

This study found that 54% of participants with androgenetic alopecia using Ricapil® showed clinical signs of hair follicle reactivation and initial hair regrowth over three months.

This study found evidence of structurally and functionally distinct AR-SARM protein complexes, which may contribute to understanding how SARMs achieve tissue-selective effects.

This study found that dimethylarsinic acid significantly accelerates skin tumor development in hair follicle-targeted K6/ODC transgenic mice.

This study reports that AhR pathway expression is significantly reduced in lymphocytes of alopecia areata patients, suggesting its potential as a diagnostic marker and therapeutic target.

JAK inhibitors are generally safe for treating alopecia areata.

This study observed that carboxytherapy significantly improved clinical and dermoscopic measures in patients with alopecia areata and androgenetic alopecia compared to placebo, though some benefits regressed during follow-up.

This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.

This article discusses the development and clinical progress of PROTAC technology, particularly focusing on the New Drug Application for vepdegestrant, an estrogen receptor-targeting PROTAC, marking significant advancements in targeted protein degradation therapies.

Dutasteride is more effective than finasteride for hair growth, and pregabalin effectively treats neuropathic pain.

This study found extensive real-world and clinical trial exposure to baricitinib across various disease states, ages, and racial populations, contributing data to its overall profile.

This study found that engineered high-affinity soluble CD200R agonists, including ARQ-234, showed superior efficacy in reducing immune responses in various preclinical models of inflammatory conditions, suggesting potential as a therapeutic for atopic dermatitis and other related diseases.

This study found a significant relationship between andropause and androgenic alopecia among civil servants at the Badung Regency Government Center.

This study reports that Abelson Interactor 1 (ABI1) regulates androgen receptor transcription in prostate cancer, identifying it as a potential target for new therapies addressing treatment resistance.

This study found that downregulating PI3K in common bean severely impaired symbiosis with beneficial microorganisms, indicating an essential role for autophagy-related processes in these mutualistic interactions.

This study tested a novel cryo-carboxy dispensing device for treating androgenetic alopecia in six volunteers and found an unexpectedly rapid and positive response, with significant hair regrowth observed by day 90, prompting early conclusion of the trial.

In this case report, a 34-year-old man experienced temporary hair loss after undergoing an endovascular procedure with fluoroscopy for facial arteriovenous malformation, which resolved within two months following treatment with topical Minoxidil and oral Cilostazol.